Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Mon., Aug. 8, 12:16 PM
Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.
| This Slide: #92 of 100 |
Slide #92. AstraZeneca — Pearl Therapeutics
Acquirer:
AstraZeneca (NASDAQ:AZN)
Acquiree:
Pearl Therapeutics
Details:
Pearl Therapeutics Inc. today announced that it has entered into a definitive merger agreement under which the Company will be acquired by AstraZeneca. The acquisition will bring together Pearl's pipeline of inhaled bronchodilator products for the treatment of patients with COPD and AstraZeneca's core capabilities in respiratory disease. The transaction was unanimously approved by the boards of directors of both companies.
AstraZeneca is a holding company. Through its subsidiaries, Co. is engaged in biopharmaceutical business focusing on the research, development and commercialization of prescription medicines. Co. focuses on disease areas that include Oncology; BioPharmaceuticals; Rare Disease; and Other Medicines and COVID-19. Key marketed products within the area of oncology include among other, Tagrisso (osimertinib) for lung cancer and Lynparza (olaparib) for ovarian cancer. Key marketed products within the area of Other Medicines and COVID-19 include among other, Synagis (palivizumab) for respiratory syncytial virus; and Evusheld (tixagevimab co-packaged with cilgavimab) for COVID-19.
Open the AZN Page at The Online Investor »
|
|||||||||||||||||||||
Open the AZN Page at The Online Investor (in a new window) »
 Free AZN Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
 
|
Buy (3.33 out of 4) 40th percentile
(ranked lower than approx. 60% of all stocks covered)
Analysts' Target Price: AZN Stock Forecast Based on Zacks ABR data; powered by Xignite |
